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InferIor petrosal sinus sampling (IPSS) is an important procedure in the diagnostic work-up of Cushing’s syn-drome. Evidence accrued over the past 3 decades lays 
the foundation for its rational use in various clinical set-
tings.
Evidence on the Use of Petrosal Sinus 
Sampling
Inferior petrosal sinus sampling entered the diagnos-
tic work-up of Cushing’s syndrome after the seminal Na-
tional Institutes of Health (NIH) publication by Oldfield 
et al.41 in 1991, which followed upon a paper by Findling 
et al.,14 published some 10 years earlier, pioneering pe-
trosal venous sampling in Cushing’s disease and ectopic 
adrenocorticotropic hormone (ACTH) secretion. The NIH 
paper described results obtained in over 200 patients and 
asserted that the maximum ratio of ACTH concentra-
tions in inferior petrosal sinus plasma to concentrations in 
peripheral-blood plasma (central/peripheral ratio), either 
at baseline sampling or after administration of corticotro-
pin-releasing hormone (CRH), provided 100% diagnostic 
accuracy for both pituitary and ectopic ACTH-secreting 
tumors.41 Subsequent studies—including some from the 
NIH itself—showed, however, that the diagnostic accuracy 
is not absolute and both false-negatives (lack of a central/
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In the management of adrenocorticotropic hormone (ACTH)–dependent Cushing’s syndrome, inferior petrosal sinus 
sampling (IPSS) provides information for the endocrinologist, the neurosurgeon, and the neuroradiologist. To the 
endocrinologist who performs the etiological diagnosis, results of IPSS confirm or exclude the diagnosis of Cushing’s 
disease with 80%–100% sensitivity and over 95% specificity. Baseline central-peripheral gradients have suboptimal 
accuracy, and stimulation with corticotropin-releasing hormone (CRH), possibly desmopressin, has to be performed. The 
rationale for the use of IPSS in this context depends on other diagnostic means, taking availability of CRH and reliability 
of dynamic testing and pituitary imaging into account. As regards the other specialists, the neuroradiologist may collate 
results of IPSS with findings at imaging, while IPSS may prove useful to the neurosurgeon to chart a surgical course. 
The present review illustrates the current standpoint of these 3 specialists on the role of IPSS.
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peripheral gradient in patients with Cushing’s disease), 
and false positives (presence of a central/peripheral gradi-
ent in patients with ectopic ACTH secretion) occur.
Table 1 describes publications reporting on the use of 
IPSS in at least 20 patients, and, as can be observed, false 
negatives may occur in 10%–15% of patients, with a high-
er prevalence on baseline, unstimulated ACTH levels. In 
detail, sensitivity of baseline central/peripheral gradients 
ranges from 54% to 96%, whereas CRH-stimulated gradi-
ents achieve 81%–100% sensitivity. These series represent 
data collected from centers in many areas of the world, 
thus false negatives are not a problem confined to single 
centers or areas. The main cause of absent ACTH gradient 
in patients harboring a pituitary ACTH-secreting tumor 
are unilateral or bilateral anatomical variants in the petro-
sal venous system. Shiu et al. originally classified 4 vari-
ants.56 In Type I, the most common variant, the petrosal 
sinus drains directly into the internal jugular vein; in Type 
II, the petrosal sinus drains into the anterior condylar vein, 
thus into both the jugular vein and the vertebral venous 
plexus; in Type III, the petrosal sinus is plexiform, and a 
network of small vessels drains into the internal jugular 
vein and the vertebral venous plexus; in Type IV, the pe-
trosal sinus drains directly into the vertebral venous plexus 
via the condylar veins, without connection to the jugular 
vein. This classification was subsequently modified, and 
the most recent version describes 6 variants, with empha-
sis on the petrosal-jugular junction.36 These variants also 
explain the less than 100% success rate of bilateral pe-
trosal cannulation and sampling (Table 1). Sampling from 
jugular veins has been employed with some success20 and 
appears a viable, fallback option if technical difficulties 
are encountered en route to the petrosal sinuses.2,28,54,67 On 
the other hand, cavernous sinus sampling does not appear 
to be superior to IPSS.31 False-negative results may also 
be due to the variability in the tumoral corticotrope secre-
tory pattern,47 and ACTH secretion by the adenoma into 
the petrosal sinuses in a given moment might not reach 
the expected 2- to 3-fold excess compared with peripheral 
concentrations. Ensuring clear hypercortisolism during 
sampling as well as using lower central/peripheral gradi-
ents20,54 may overcome this problem.
TABlE 1. Summary of case series reporting on IPSS in at least 20 patients*
Cushing’s Disease† Ectopic ACTH‡ Successful 
CannulationAuthors & Year Location Baseline Post-CRH Baseline Post-CRH
Oldfield et al., 1991 Bethesda 205/215 (95%) 203/203 (100%) 20/20 17/17 99%
Findling et al., 1991 Milwaukee 18/20 (90%) 17/18 (94%) 9/9 6/6 93%
Tabarin et al., 1991 Bordeaux 18/22 (82%) 22/22 (100%) 5/5 5/5 89%
López et al., 1996 Madrid 27/30 (90%) 22/25 (88%) 94%
Landolt et al., 1994 Zurich 33/38 (87%) 37/38 (95%) —
Zarilli et al., 1995 Naples 12/22 (54%) 19/22 (86%) 4/4 4/4 85%
Booth et al., 1998 Toronto 24/26 (84%) 91%
Teramoto et al., 1998 Tokyo 27/35 (77%) 5/5 —
Kaltsas et al., 1999 London 50/68 (72%) 64/69 (93%) 6/6 6/6 73%
Invitti et al., 199923 Italy§ 69/85 (81%) 65/76 (85%) 9/10 10/10 —
Bonelli et al., 2000 Mayo Clinic 48/54 (89%) 47/54 (87%) 9/9 8/9 87%
Wiggam et al., 2000 Belfast 36/44 (82%) 1/1 —
Lefournier et al., 2003 Grenoble 71/74 (96%) 74/74 (100%) 12/12 10/12 —
Liu et al., 2004 Cleveland 39/42 (93%) 21/22 (95%) 9/9 7/7 —
Ilias et al., 2004 Bethesda 58/65 (89%) 59/65 (91%) 13/13 13/13 92%
Kalgikar et al., 2005 Mumbai 23/34 (68%) 4/4 100%
Kaskarelis et al., 2006 Athens 57/63 (90%) 12/12 12/12 81%
Jehle et al., 2008 New York 103/105 (98%) 97%
Daousi et al., 2010 Liverpool 21/24 (87%) 21/24 (87%) 2/2 2/2 69%
Shi et al., 2011 Shanghai 57/64 (89%) 4/5 100%
Mulligan et al., 2011 Cleveland 33/35 (94%) 33/35 (94%) 1/1 —
Andereggen et al., 2012 Bern 17/20 (85%) 19/20 (95%) 2/3 2/3 96%
Sheth et al., 2012 Boston 194/296 (94%) 9/11 83%
Grant et al., 2012 London 67/83 (81%) 10/10 —
Wind et al., 2013 Bethesda 467/501 (93%) 487/500 (97%) 99%
*  Some series from the same center might contain duplicate data. The most recent series from a given center is listed in case of multiple publications on the same 
patient database. Diagnostic criteria as defined by Oldfield et al.:41 Cushing’s disease is defined as a central/peripheral baseline ACTH gradient ≥ 2 or post-CRH ≥ 3; 
ectopic ACTH secretion is defined as a central/peripheral baseline ACTH gradient < 2 or post-CRH < 3. 
†  Number of true positives over total number of patients with Cushing’s disease tested (sensitivity). 
‡  Number of true negatives over total number of patients with ectopic ACTH secretion tested.
§  Multicenter study.
Neurosurg Focus  Volume 38 • February 20152
Role of IPSS in cushing’s syndrome
In addition to false negatives, a small portion of patients 
bearing an extrapituitary ACTH-secreting tumor present 
an unexpected central/peripheral ACTH gradient. A scat-
tering of cases have been reported in major case series 
(Table 1) as well as in individual case reports.9,30,42,58,62,69 
Overall, although the paucity of reported cases allows only 
an approximate calculation, the specificity of IPSS may be 
estimated at 90%–95%. In a number of these cases, pa-
tients were subjected to transsphenoidal surgery, but the 
postoperative course suggested an ectopic source, and the 
causative lesion—in some cases already evident prior to 
pituitary surgery but deemed incidental at the time—was 
subsequently removed. Some tumors were documented 
to secrete both ACTH and CRH,30,69 a credible explana-
tion for false-positive results, or were located close to the 
pituitary (e.g., esthesioneuroblastoma or sphenoidal sinus 
ectopic pituitary adenoma).21,62 It has been suggested that 
false positives could be due to intermittent hypercorti-
solism and sampling performed by chance in the eucorti-
solemic state;68 this implies that normal corticotropes rap-
idly recover their secretory pattern as soon as cortisol lev-
els decrease, which contrasts, however, with long-standing 
secondary adrenal insufficiency after curative surgery for 
Cushing’s syndrome due to any cause. For the most part, 
the cause of false-positive IPSS results remained elusive 
in patients with proven ectopic ACTH-secreting tumors.
Altogether, given the different prevalence of the 2 eti-
ologies of ACTH-dependent Cushing’s syndrome, with 
pituitary outnumbering ectopic secretion by 4–5 to 1, it 
appears evident that any patient without a central/periph-
eral gradient is still more likely to harbor a pituitary rather 
than an extra-pituitary tumor. Indeed, this justified trans-
sphenoidal surgery in all those patients in whom IPSS re-
sults were proven false by the success of pituitary surgery. 
In these patients, dynamic testing and/or pituitary imaging 
pointed toward a pituitary origin and no extra-pituitary le-
sion was evident, thus supporting pituitary exploration.
The data reported so far rest on measurement of ACTH 
in the petrosal sinus, the most rational approach to con-
firming the presence of a corticotrope tumor; however, the 
tumor might secrete additional pituitary-derived peptides, 
such as growth hormone, prolactin, thyroid-stimulating 
hormone, alpha subunit, alternative proopiomelanocortin 
breakdown products (e.g., b-endorphin),50 or non–pitu-
itary-derived factors (e.g., atrial natriuretic factor, interleu-
kin-1 receptor antagonist, tumor necrosis factor alpha, or 
parathyroid hormone–related protein).34,65 Of these, only 
prolactin has proven of some use to attest to successful 
catheterization.15 Furthermore, in some patients without 
a central/peripheral gradient, normalizing the ACTH ra-
tio by prolactin pointed toward a pituitary origin,18,53 thus 
reversing a false-negative result. However, proposed cut-
offs for pituitary or ectopic secretion vary, and an area 
of uncertainty remains.52 The prolactin inter-sinus ratio 
has been used to predict tumor localization within the pi-
tuitary, as it is known that the ACTH inter-sinus ratio is 
correct in less than 70% of cases.67 However, even with 
the prolactin-adjusted ACTH ratio, tumor site prediction 
is by no means absolute.39 Altogether, the measurement 
of prolactin proved useful in selected cases, mostly with 
negative gradients, but whether it provides meaningful, 
adjunctive information and should be assessed routinely 
remains to be established.
As regards baseline versus stimulated ACTH gradients, 
as mentioned above, most series report greater sensitiv-
ity after CRH stimulation, thus supporting its use during 
IPSS to maximize diagnostic accuracy. Nevertheless, CRH 
is not readily available worldwide, and desmopressin, an 
alternative stimulant for tumoral ACTH secretion,37,49 has 
been employed. Approximately 150 patients with Cush-
ing’s disease tested with desmopressin have been reported 
on so far,4,10,33 with the results showing sensitivity compa-
rable to that of CRH stimulation (i.e., 90%–97%). Stimula-
tion with desmopressin and CRH together, performed to 
amplify corticotrope responses, identified a central/periph-
eral ACTH gradient in 46 of 47 patients with Cushing’s 
disease.63 The use of desmopressin however might mandate 
additional precautions during the sampling procedure, as 
this agent is a known hemostatic and causes release of von 
Willebrand factor as well as other factors of the coagula-
tory cascade in patients with Cushing’s disease.46
In this context, it is worth recalling that IPSS is an in-
vasive maneuver that requires specific expertise to achieve 
successful bilateral cannulation and accurate and coordi-
nated blood sampling and minimize untoward effects. 
Minor complaints during or after petrosal sampling have 
included tinnitus or otalgia (1%–2%) and groin swelling 
or hematoma (2%–3%). More serious complications—
both neurological (nerve palsy [1%], subarachnoid hemor-
rhage, brainstem infarction, or contrast extravasation) and 
peripheral (e.g., pulmonary and deep vein thromboembo-
lism)—have been reported but appear extremely rare.35,61 
Developments in endovascular materials, such as smaller, 
hydrophilic catheters and microcatheters and pressurized 
sacks for continuous catheter flushing, may minimize the 
risks of thromboembolic and hemorrhagic events. Unilat-
eral femoral vein puncture using 9-Fr sheaths may reduce 
groin complications in obese patients.43
Rationale for the Use of Petrosal Sinus  
Sampling
Petrosal sinus sampling can yield 2 different types of 
evidence: 1) it can differentiate between pituitary and ec-
topic tumoral ACTH secretion, and 2) it can provide clues 
as to the site of a patient’s pituitary adenoma (i.e., midline 
or right or left of midline). The endocrinologist is obvi-
ously interested in achieving the correct differential di-
agnosis, whereas the neurosurgeon also benefits from any 
information as to the location of the adenoma.
Series reporting on the use of IPSS have adopted differ-
ent strategies—for example, performing the procedure in 
any patient with ACTH-dependent Cushing’s syndrome, 
only in patients with ACTH-dependent Cushing’s syn-
drome and equivocal responses to dynamic testing (CRH 
stimulation and/or high-dose dexamethasone suppres-
sion), or only in patients in whom pituitary imaging failed 
to visualize an adenoma, regardless of results of dynamic 
testing. In patients with clear-cut responses to CRH and/
or 8-mg dexamethasone and some evidence of a pituitary 
adenoma, IPSS is usually not performed.
These strategies all have pros and cons. The abridged 
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strategy for IPSS in any patient with Cushing’s syndrome, 
detectable ACTH levels, and normal or equivocal findings 
on pituitary imaging is based on an epidemiological prem-
ise—that is, that Cushing’s disease is by far the more like-
ly diagnosis and that dynamic testing does not add to (and 
may even detract from) this a priori probability. Arguing 
against this approach is the risk of false negatives at IPSS, 
which—in the absence of supportive results from dynamic 
testing—may divert the patient from appropriate surgery. 
Furthermore, IPSS may prove inconclusive due to failure 
to correctly cannulate the petrosal sinuses (see Table 1); 
indeed, a large series detailing unsuccessful IPSS showed 
that a pituitary source was detected at surgery in over 85% 
of cases.54 Of note, this strategy has even led to petrosal 
sampling in patients with adrenal Cushing’s syndrome 
and unsuppressed plasma ACTH concentrations.28,54
In other series, IPSS was performed in patients with 
equivocal responses to dynamic testing, usually to con-
firm the diagnosis of Cushing’s disease.22,60 CRH stimula-
tion has proven the most accurate, non-invasive approach 
to differentiate between pituitary and ectopic tumors,45,48 
but CRH is expensive and not widely available. In con-
trast, high-dose dexamethasone suppression can be easily 
performed but is less accurate. Indeed, to obtain certainty 
of pituitary disease, the criterion for cortisol suppression 
needs to be set at 80%–90% of pretest concentrations, 
and this, in turn, increases the number of non-suppres-
sors among patients with Cushing’s disease.12,17,23 On the 
other hand, the likelihood of false-positive responses to 
both the CRH test and the 8-mg dexamethasone test in 
patients with ectopic ACTH secretion using appropriate 
response criteria appears very low.1,21,40,64 Of note, false-
positive IPSS results have been reported in patients with 
false-positive responses to these tests.58,62,69
Lastly, IPSS has been used in patients with ACTH-
dependent Cushing’s syndrome who did not present a 
clear pituitary lesion, even though testing was indicative 
of a pituitary lesion. This approach is burdened by the 
low prevalence of visible pituitary tumors in patients with 
Cushing’s disease; indeed, even the most sensitive pitu-
itary imaging techniques proved negative in 20%–50% of 
patients in whom an ACTH-secreting adenoma was con-
firmed by surgery.44 Furthermore, incidental pituitary le-
sions have been described in the general population,19 in 
patients with ectopic ACTH secretion,1,3,21 and in patients 
with Cushing’s disease.8 With respect to this latter group, 
this observation is supported by the fact that concordance 
between adenoma site prediction at imaging and location 
at pituitary surgery is by no means absolute (i.e., has been 
reported to be as low as 50%).8 Reported data refer to im-
aging performed mostly prior to the advent of newer, more 
sensitive MRI equipment (1.5-, 3-, and in the future even 
7-T units), and findings could therefore change over the 
next few years. Whether the increased sensitivity for these 
small adenomas is offset by an increased detection rate of 
pituitary incidentalomas remains to be seen.
On the other hand, in patients with a high likelihood 
of Cushing’s disease and without visible evidence of a pi-
tuitary adenoma, IPSS may provide adjuvant information 
to the neurosurgeon rather than be required to complete 
the diagnostic work-up. The main challenge in these pa-
tients is in fact careful exploration of the pituitary gland 
in search of a microadenoma. Most authors agree that 
IPSS should, at most, suggest the side of the gland to be 
explored first; however, a thorough exploration is usually 
recommended even after an initial finding because contra-
lateral ACTH-secreting pituitary adenomas have been de-
scribed.13 As to technical issues, pituitary gland explora-
tion requires specific training: one possible, quite common 
pitfall is to interpret small seepage due to pituitary tissue 
manipulation or squeezing as a microadenoma.51 Color 
and consistency of the tumor are easily recognized by the 
experienced neurosurgeon, as ACTH-secreting adenomas 
are usually whitish and soft. Further, care should be taken 
during tumor collection to avoid inadvertent tumor speci-
men aspiration. Filters in the suction system may be of use 
to collect aspirated surgical specimens, but these are often 
too small for pathology, thus definite proof of tumor re-
moval is not obtained. No study has yet evaluated whether 
more extensive pituitary exploration due to misleading or 
absent lateralization at IPSS is linked to postsurgical hy-
popituitarism, but this is not an unreasonable assumption. 
This argument may prove particularly significant in chil-
dren with Cushing’s disease, in whom pituitary imaging is 
often inconclusive.25
As regards the influence of IPSS on remission rates, 
both older5 and more recent24 studies have shown that 
outcome of pituitary surgery is comparable in patients 
who have or have not undergone IPSS prior to surgery. 
Moreover, detection of the pituitary adenoma and remis-
sion were also extensively proven in patients with nega-
tive central/peripheral ratios (see Table 1); indeed, proof of 
Cushing’s disease by either was a prerequisite to assert a 
false-negative result. Thus, negative IPSS does not appear 
to affect likelihood of remission.
conclusions
The endocrinologist, neuroradiologist, and neurosur-
geon have different but overlapping expectations from 
IPSS. The endocrinologist might need to confirm the di-
agnosis, the neuroradiologist to locate the adenoma, and 
the neurosurgeon to direct pituitary surgery. Altogether, 
these requirements establish the framework for the role 
of IPSS in Cushing’s syndrome, as discussed by members 
of the Italian Society for Endocrinology (SIE), Italian So-
ciety for Neurosurgery (SINCh), and Italian Society for 
Neuroradiology (AINR) during the meeting “Altogether 
to Beat Cushing’s Syndrome.”
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